Candel Therapeutics, Inc.
CADL Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$8.03
KIRA · Stoqly’s AI analyst, in plain words
- Candel Therapeutics, Inc. lost $38.2M in fiscal 2025.
- Free cash flow was −$38.9M in fiscal 2025, — of revenue.
- Candel Therapeutics, Inc. has $120M more cash than debt.
Market cap
$595M
P/E
—
Revenue
—
Net income
−$38.2M
Free cash flow
−$38.9M
Operating margin
—
Candel Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$38.2M
No. It lost money last year.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Candel Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 12, 2026
- Legal name
- Candel Therapeutics, Inc.
- CIK
- 0001841387
Candel Therapeutics, Inc. · CADL
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.1M | $0.1M | — | — | — |
| Revenue growth | 0.0% | 0.0% | — | — | — |
| Operating margin | −20,580.8% | −27,777.6% | — | — | — |
| Net income | −$36.1M | −$18.8M | −$37.9M | −$55.2M | −$38.2M |
| Net margin | −28,899.2% | −15,035.2% | — | — | — |
| Diluted EPS | −$1.91 | −$0.65 | −$1.31 | −$1.74 | −$0.72 |
| Cash | |||||
| Cash from operations | −$22.2M | −$31.4M | −$34.2M | −$27.0M | −$38.3M |
| Capital expenditure | $1.8M | $1.3M | $0.5M | $0.0M | $0.6M |
| Free cash flow | −$24.1M | −$32.7M | −$34.7M | −$27.0M | −$38.9M |
| FCF margin | −19,242.4% | −26,172.8% | — | — | — |
| Share count change | 62.5% | 52.7% | 0.4% | 9.5% | 67.2% |
| Debt and strength | |||||
| Cash and short-term investments | $82.6M | $70.1M | $35.4M | $103M | $120M |
| Debt incl. finance leases | $0.6M | — | $20.5M | $11.6M | $0.0M |
| Shareholders' equity | $64.1M | $47.7M | $12.7M | $66.3M | $51.9M |
| Current ratio | 15.8x | 12.8x | 2.6x | 2.8x | 13.5x |
| Interest coverage | — | −20.3x | — | −16.0x | −22.8x |
| Returns and quality | |||||
| Return on equity | −178.1% | −33.6% | −125.5% | −139.6% | −64.6% |
| Return on tangible equity | −56.3% | −39.4% | −297.7% | −83.2% | −73.5% |
| Piotroski F-score | 4 | 2 | — | 4 | 3 |
| Altman Z'' | 3.7 | 0.1 | −13.0 | −2.2 | −2.0 |
Insiders bought, 12 months
$3.0M
1 insider
Insiders sold, 12 months
$3.6M
3 insiders
Of sales under plans
100%
$3.6M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Candel Therapeutics, Inc. · CADL
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $8.03 a share, the company is worth $595M.
Source: SEC EDGAR XBRL filings (CIK 0001841387). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.